“Let's assume that the number of metastatic patients present in Italy is equal to 100, we know that the patients potentially eligible for this drug are approximately 75% of this proportion. Therefore, only women who have a Her2 positive disease and who already receive this same drug are excluded from this category.” Thus Giampaolo Bianchini, professor and head of the breast group of the Irccs San Raffaele hospital – Vita-salute San Raffaele university of Milan, on the sidelines of the press conference 'Breast cancer: the new frontiers of treatment', organized in Milan by AstraZeneca and Daiichi Sankyo. At the center of the conference, dedicated to the presentation of new perspectives for the treatment of metastatic breast cancer with low levels of expression of the Her2 receptor, is the monoclonal antibody drug conjugate trastuzumab deruxtecan, whose reimbursement has been approved by Aifa also for this type of patients.
#Breast #cancer #Bianchini #San #Raffaele #drug #eligible #metastatic #patients
